TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia/reperfusion injury in mice

Fang Hua, Emory University
Huiling Tang, Emory University
Jun Wang, Emory University
Megan C. Prunty, Emory University
Xiaodong Hua, University of Georgia
Iqbal Sayeed, Emory University
Donald Stein, Emory University

Journal Title: Journal of Cerebral Blood Flow and Metabolism
Volume: Volume 35, Number 4
Publisher: SAGE Publications (UK and US) | 2015-04-01, Pages 536-542
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1038/jcbfm.2014.240
Permanent URL: https://pid.emory.edu/ark:/25593/rxtg1

Final published version: http://dx.doi.org/10.1038/jcbfm.2014.240

Copyright information:
© 2015 International Society for Cerebral Blood Flow & Metabolism, Inc. This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License (http://creativecommons.org/licenses/by-nc-sa/3.0/).

Accessed July 26, 2019 5:07 AM EDT
RAPID COMMUNICATION

TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia/reperfusion injury in mice

Fang Hua1,2,3, Huiling Tang3, Jun Wang3, Megan C Prunty3, Xiaodong Hua4, Iqbal Sayeed3 and Donald G Stein3

Toll-like receptor 4 (TLR4) contributes to cerebral ischemia/reperfusion (I/R) injury and is a potential target for the treatment of ischemic stroke. This experiment is to evaluate the effect of an exogenous TLR4 antagonist, TAK-242, against acute cerebral I/R injury. A mouse model of cerebral I/R was induced by transient middle cerebral artery occlusion. TAK-242 (3 mg/kg body weight) was injected intraperitoneally 1 hour after ischemia. Our results showed that the concentration of TAK-242 in plasma increased to 52.0 ng/mL 3 hours after injection, was maintained at 54.1 ng/mL 8 hours after injection, and decreased to 22.6 ng/mL 24 hours after injection. The concentration of TAK-242 in brain tissue increased to 26.1 ng/mL in ischemic hemisphere and 14.2 ng/mL in non-ischemic hemisphere 3 hours after injection, and was maintained at the similar levels 24 hours after injection. We found that TAK-242 significantly reduced cerebral infarction compared with vehicle control, improved neurologic function, inhibited the phosphorylation of downstream protein kinases in TLR4 signaling pathway, and downregulated the expression of inflammatory cytokines. We conclude that TAK-242 is able to cross blood-brain barrier, blocks TLR4 signaling, mediates the expression of inflammatory cytokines, and protects the brain from acute damage induced by I/R.


Keywords: cerebral ischemia/reperfusion; neuroprotection; TAK-242; Toll-like receptors

INTRODUCTION

Cerebral ischemia is usually the result of the obstruction of brain arteries and lack of blood supply to the brain. Although therapies for the restoration of blood flow to brain tissue are effective, reperfusion in the ischemic brain leads to a cascade of pathophysiologic processes resulting in further damage known as ischemia/reperfusion (I/R) injury. A growing body of evidence suggests that cerebral I/R induces robust in situ inflammatory responses that contribute to further injury including neuronal death and white-matter damage.1-3

Toll-like receptors (TLRs) are transmembrane pattern-recognition receptor family with important roles in the induction and regulation of immune/inflammatory responses. Toll-like receptor 4 is believed to be involved in several pathologies such as sepsis, cardiac diseases,4 and I/R injury.5-7 Our studies and others have revealed that TLR4-mediated signaling is activated after ischemia and contributes to increased inflammatory responses and further brain injury.7 Resatorvid (TAK-242), an exogenous synthetic antagonist for TLR4, is a small molecule which binds selectively to TLR4 and inhibits TLR4 signal transduction and its downstream signaling events.8-10 However, whether TAK-242 can pass through the blood-brain barrier (BBB) and inhibit neuroinflammation in ischemic brain has not been investigated. The present study evaluated the ability of TAK-242 to pass through the BBB, its neuroprotective effect, and its modulation on inflammatory cytokines after acute cerebral I/R in mice.

MATERIALS AND METHODS

Animals

Sixty-two male mice (C57BL/6; age 12 weeks; body weight 25–30 g) were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and maintained in the Division of Animal Resources at Emory University. The experiments outlined in this manuscript conform to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. The animal care and experimental protocols were approved by the Emory University Institutional Animal Care and Use Committee.

In the experiment to evaluate the protective effect of TAK-242 against ischemia injury, mice were randomly assigned to four groups: (1) sham surgery treated with 1% dimethyl sulfoxide (DMSO, vehicle) as sham vehicle control (S, n = 9; four mice were used for molecular analysis); (2) focal cerebral I/R treated with 1% DMSO as I/R plus vehicle control (I/R, n = 17; five mice were used for molecular analysis); (3) sham surgery treated with TAK-242 (S-T, n = 9; four mice were used for molecular analysis); and (4) focal cerebral I/R treated with TAK-242 (I/R-T n = 17; five mice were used for molecular analysis).

In another experiment, 10 mice were used to evaluate the concentration of TAK-242 in plasma and brain tissue. One mouse (naive, without any treatment) was used as blank control, and 9 mice subjected to cerebral I/R treated with TAK-242 were used to evaluate the concentration of TAK-242 in plasma and brain tissue 3, 8 and 24 hours after intraperitoneal injection (three mice for...
mixed with 0.05 mL sodium citrate. The samples were incubated at 37°C. Heart rate and partial pressure of oxygen were monitored during surgery. After the skin incision, the left common carotid artery, the external carotid artery, and the internal carotid artery were carefully exposed. Microvascular aneurysm clips were applied to the left common carotid artery and the internal carotid artery. A coated 6-0 filament (6023PK, Doccol Corp., Redlands, CA, USA) was introduced into an arteriotomy hole, fed distally into the internal carotid artery and advanced 11 mm from the carotid bifurcation. The internal carotid artery clamp was removed and focal cerebral ischemia started. After ischemia for 60 minutes, the filament and the common carotid artery clamp were gently removed (reperfusion starts). The collar suture at the base of the external carotid artery stump was tightened. The skin was closed, anesthesia was discontinued, and the animal was allowed to recover in a prewarmed cage. Sham control mice underwent a neck dissection and coagulation of the external carotid artery, but without middle cerebral artery occlusion. Ischemia and reperfusion conditions were confirmed by the regional cerebral blood flow (rCBF) detected by a laser Doppler cerebral flow meter (moorVMS-LDF, Moor Instruments, Delaware, DE, USA) before cerebral ischemia, during cerebral ischemia, and after reperfusion.

**TAK-242 Treatment**

TAK-242 was dissolved in DMSO and then diluted in sterile endotoxin-free water. The final concentration of DMSO was 1%. The dissolved TAK-242 or DMSO (1%) was injected intraperitoneally (3 mg/kg body weight) 1 hour after middle cerebral artery occlusion or sham surgical operation. This optimal dose was selected based on previous studies. The route of administration was modified to intraperitoneal injection.

**Evaluation of Neurologic Score**

All the mice were scored by an investigator who was masked using the method described previously with modification. The scoring system ranges from 0 to 15, in which 0 is death because of cerebral I/R injury, and 15 is a perfect score. Briefly, the scoring system includes five principal tasks for survival mice: spontaneous activity over a 3-minute period (0 to 3), symmetry of movement (0 to 3), open-field path linearity (0 to 3), beam walking on a 3 cm × 1 cm beam (0 to 3), and response to vibrissae touch (1 to 3). If the mouse died from cerebral I/R injury, the animal received a 0 point.

**Measurement of TAK-242 Concentration in Plasma and Brain Tissue**

Three, 8, or 24 hours after the injection of TAK-242, the mice were anesthetized with 5.0% isoflurane driven by 100% oxygen flow. Blood (0.95 mL) was drawn from the left ventricle and immediately mixed with 0.05 mL sodium citrate. The samples were incubated at room temperature for 30 minutes and centrifuged at 8,000 r.p.m. The plasma was collected and stored at −80°C for future use. Immediately after the blood was drawn, the mice were perfused with ice-cold normal saline via the ascending aorta until the perfusion buffer was clear from the right atrium. The brains were removed and weighed. Brain tissues were homogenized with buffer and centrifuged at 14,000 r.p.m. for 10 minutes. Supernatants were collected and stored at −80°C. The concentrations of TAK-242 were detected by Intertek (El Dorado Hill, CA, USA) using liquid chromatography with tandem mass spectrometry detection. Briefly, TAK-242 and internal standard (bromfenac) were extracted from 50 μL of mouse plasma or brain homogenate by liquid-liquid extraction using methyl tertiary-butyl ether. After evaporation to dryness and reconstitution, the extracts were analyzed by liquid chromatography with tandem mass spectrometry. Run times were 5 minutes. The lower limit of quantitation for TAK-242 is 0.5 ng/mL for plasma, and 2 ng/g for brain homogenate. The calibration curve range is 0.5–2,000 ng/mL for plasma, and 2–4,000 ng/g for brain homogenate. The concentrations of TAK-242 were calculated based on the standard curve.

**Antibody Array**

Six hours after cerebral ischemia, mice were killed and perfused with ice-cold phosphate-buffered saline via the ascending aorta. Ischemic cerebral hemispheres were removed and stored at −80°C. Proteins were prepared from ischemic cerebral hemispheres. Forty inflammatory cytokines were analyzed by antibody arrays (RayBio Cytokine Antibody Arrays—Mouse Inflammation Antibody Array G Series I, RayBiotech, Norcross, GA, USA). Briefly, the glass chips were air dried for 60 minutes and assembled into an incubation chamber and incubation frame. Blocking buffer (100 μL) was added into each well and the glass chips were incubated at room temperature for 30 minutes. After decanting the blocking buffer, 100 μL of each sample was added and incubated at 4°C overnight. The chips were washed five times with wash buffer I and then two times with wash buffer II at room temperature; 70 μL of diluted biotin-conjugated antibodies was added to each corresponding well, and the chips were incubated at 4°C overnight. The chips were washed as previously described and 70 μL of diluted Alexa Fluor 555–conjugated streptavidin was added to each subarray. The incubation chamber was covered with an adhesive film and aluminum foil, and incubated at 4°C overnight. The chips were washed two times with wash buffer I. The incubation frame and chamber were disassembled. The slides were taken out and placed in a 50-μL centrifuge tube, washed twice with wash buffer I at room temperature for 10 minutes each time, washed once with wash buffer II for 10 minutes, and rinsed with distilled H2O. The water droplets were removed by centrifuge at 1,000 r.p.m. for 3 minutes and then dried completely in air for at least 20 minutes while protected from light. The slides were scanned using a laser scanner (Axon GenePix, Molecular Devices, Sunnyvale, CA, USA) with a Cy3 channel. Signal data were collected and analyzed by a software from RayBiotech (Norcross, GA, USA).
Western Blots

Western blotting was performed as described previously. Briefly, proteins were extracted from the brain samples harvested 6 hours after cerebral ischemia, electrophoresed with sodium dodecyl sulfate polyacrylamide gel, and transferred onto Hybond ECL membranes (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The ECL membranes were incubated with primary antibody followed by incubation with peroxidase-conjugated secondary antibodies. Signals were detected with the ECL system (Amersham Pharmacia Biotech) and quantified by scanning densitometry and computer-assisted image analysis. The primary antibodies used were anticyclooxygenase-2 (anti-COX-2), antimatrix metallopeptidase 9 (anti-MMP-9), anti-p-IκB kinase α/β (anti-p-IKKα/β), anti-IκKα, anti-p-inhibitor of nuclear factor kappa B alpha (anti-p-IκBa), anti-IκBa, and anti-beta actin (Cell Signaling Technology, Danvers, MA, USA).

Statistical Analysis
Continuous scale measurements were expressed as mean ± s.e.m. for each group. Neurologic function (neurologic score) was analyzed by Kruskal-Wallis analysis of variance on ranks. After normality testing (Shapiro-Wilk method) and equal variance tests were passed, all pair-wise multiple comparison procedures (Dunn’s method) were performed. A value of *P < 0.05 was considered to be significant. The concentration of TAK-242 was analyzed by repeated measures analysis of variance, and the size of infarction and the levels of inflammatory cytokines were analyzed by one-way analysis of variance. Pair-wise comparisons of group means (Holm-Sidak method) were used to compare group means after normality testing (Shapiro-Wilk) and equal variance tests were passed. A probability level of 0.05 or smaller was used to indicate statistical significance.

RESULTS

Concentration of TAK-242 in Plasma and Brain Tissue

The concentrations of TAK-242 in plasma and brain tissue were measured at different time points after intraperitoneal injection using liquid chromatography with tandem mass spectrometry. Our results showed that the concentration of TAK-242 in plasma increased to 52.0 ng/mL 3 hours after treatment, was maintained at 54.1 ng/mL 8 hours after treatment, and decreased to 22.6 ng/mL 24 hours after treatment. The concentration of TAK-242 in brain tissue increased to 26.1 ng/mL (ipsilateral) and 14.2 ng/mL (contralateral) 3 hours after treatment, was maintained at 26.4 ng/mL (ipsilateral) and 15.1 ng/mL (contralateral) 8 hours after treatment, and was still maintained at 25.0 ng/mL (ipsilateral) and 17.5 ng/mL (contralateral) 24 hours after treatment (Figure 1).

Infarct size and Neurologic Score

During ischemia, rCBF decreased to < 80% of normal levels (before ischemia), and after reperfusion, rCBF recovered to > 75% of normal, which confirmed the success of the animal model. Infarct size and neurologic score were measured 24 hours after cerebral I/R or sham surgery. Our data showed that sham surgery treated with vehicle (S) and sham surgery treated with TAK-242 (S-T) did not induce any cerebral infarction. The infarct sizes were 21.3% in the untreated I/R group (I/R) and 12.5% in the TAK-242-treated I/R group (I/R-T). TAK-242 treatment significantly reduced brain infarct size by 41% compared with the untreated mice (P < 0.05; Figure 2).

Our data also showed that sham surgery treated with TAK-242 (S-T) did not induce significant neurobehavioral changes compared with sham surgery treated with vehicle (S). Cerebral I/R significantly reduced neurologic score (4.38) compared with sham surgery treated with vehicle (S) and sham surgery treated with TAK-242 (S-T, P < 0.05; Figure 2). The mice subjected to cerebral I/R treated with TAK-242 did not show significant difference from S and S-T, which indicated that TAK-242 treatment could improve neurologic function impaired by cerebral I/R.

Protein Array

Levels of 40 inflammatory cytokines were detected 6 hours after cerebral I/R using an antibody array. Our data showed that the levels of soluble tumor necrosis factor receptor I, soluble tumor necrosis factor receptor II, chemokine (C-X-C motif) ligand 1 (CXCL1), granulocyte colony-stimulating factor, interleukin-6, monocyte chemotactic protein-1, macrophage inflammatory protein-1γ (MIP-1γ), and tissue inhibitor of metalloproteinases 1 (TIMP-1) significantly increased in ischemic brain compared with sham controls (P < 0.05; Figures 3 and 4). Treatment with TAK-242 significantly reduced the levels of soluble tumor necrosis factor receptor II, monocyte chemotactic protein-1, MIP-1γ, and TIMP-1 compared with untreated controls (P < 0.05; Figure 4).

DISCUSSION

Cerebral I/R triggers acute inflammation which aggravates cerebral ischemic injury. One of the important mechanisms of this process is the activation of the innate immune system. TLRs play important roles in the induction and regulation of immune/inflammatory responses. To date, 13 TLRs have been identified in mammals. Each TLR can recognize its distinct ligands derived from various microorganisms or released from damaged tissues. On activation by exogenous and endogenous ligands, TLRs recruit their adapter proteins, activate downstream kinases, and then induce the expression of inflammation-associated genes. Previous studies indicated that TLR4-mediated signaling was activated in ischemic brain, and that TLR4-deficient attenuated cerebral ischemic injury in TLR4 knockout mice. Exogenous synthetic antagonists for TLR4, such as resatorvid (TAK-242), can
Figure 2. Brain infarct size and neurologic score 24 hours after cerebral I/R or sham surgery. The image shows that sham surgery treated with vehicle (S) and sham surgery treated with TAK-242 (S-T) did not induce any cerebral infarction. TAK-242 treatment significantly reduced brain infarct size (12.5%) compared with untreated mice (21.3%; #P < 0.05). TAK-242 treatment significantly improved neurologic function (6.73) compared with untreated mice (4.38; #P < 0.05). A representative picture of 2,3,5-triphenyltetrazolium chloride (TTC) staining is shown on the top of the image. In addition, treatment with TAK-242 (S-T) did not induce significant neurobehavioral changes compared with sham surgery treated with vehicle (S). Cerebral I/R significantly reduced neurologic score (4.38) compared with sham surgery treated with vehicle (S, *P < 0.05). The mice subjected to cerebral I/R treated with TAK-242 did not show significant difference from S-T, which indicated that TAK-242 treatment could improve neurologic function impaired by cerebral I/R.

Figure 3. Levels of sTNF RI, KC, GCSF, and IL-6 in brain tissue 6 hours after cerebral I/R. The levels of sTNF RI, KC, GCSF, and IL-6 significantly increased in ischemic brain compared with sham controls (*compared with sham, P < 0.05). GCSF, granulocyte colony-stimulating factor; I/R, ischemia/reperfusion; I/R-Tak, I/R treated with TAK-242; IL-6, interleukin-6; S-Tak, sham control with TAK-242; sham, sham control; sTNF RI, soluble tumor necrosis factor receptor-I; KC, chemokine (C-X-C motif) ligand.
block TLR4 signaling and inhibit the inflammatory responses in experimental sepsis. The specificity of TAK-242 was confirmed by several studies. TAK-242 binds selectively to TLR4, and is a selective inhibitor of signaling from the intracellular domain of TLR4. TAK-242 can disrupt the interaction of TLR4 with adapter molecules, and thereby inhibit TLR4 signal transduction and its downstream signaling events. TAK-242 represents a novel therapeutic approach to the treatment of TLR4-mediated cerebral ischemic injury.

Figure 4. Levels of sTNF RII, MCP-1, MIP-1γ, and TIMP-1 in brain tissue 6 hours after cerebral I/R. Levels of sTNF RII, MCP-1, MIP-1γ, and TIMP-1 significantly increased in ischemic brain compared with sham controls (#compared with sham, P < 0.05). Treatment with TAK-242 significantly reduced the levels of these cytokines compared with untreated controls (*compared with I/R, P < 0.05). I/R, ischemia/reperfusion; I/R-Tak, I/R treated with TAK-242; MCP-1, monocyte chemotactic protein-1; MIP-1γ, macrophage inflammatory protein-1γ; S-Tak, sham control with TAK-242; sham, sham control; sTNF, soluble tumor necrosis factor; TIMP-1, tissue inhibitor of metalloproteinases 1.

Figure 5. Phosphorylation of IKKa/β and IκBα in brain tissue 6 hours after cerebral I/R. The phosphorylation of IKKa/β and IκBα significantly increased in ischemic brain compared with sham controls (#compared with sham, P < 0.05). Treatment with TAK-242 significantly inhibited the phosphorylation of IKKa/β and IκBα compared with untreated controls (*compared with I/R, P < 0.05). I/R, ischemia/reperfusion; I/R-Tak, I/R treated with TAK-242; IκBα, inhibitor of nuclear factor kappa B alpha; IKKa/β, IκB kinase α/β; S-Tak, sham control with TAK-242; sham, sham control.
diseases.\textsuperscript{21,22} However, whether TAK-242 has neuroprotective effects on ischemic brain remains unknown. To investigate whether TAK-242 can pass through the BBB and protect the brain from cerebral I/R, we measured the concentration of TAK-242 in plasma and brain tissue, and evaluated ischemia-induced inflammation and subsequent brain damage in mice treated with TAK-242.

We used C57BL/6J mice to establish the model of cerebral I/R. Body temperature, heart rate, and partial pressure of oxygen were monitored during surgery, and there was no significant difference in these parameters between the TAK-242-treated and the untreated groups. Results from rCBF detected by a laser Doppler cerebral flow meter (moorVMS-LDF) showed that during ischemia, rCBF decreased to $<80\%$ of normal levels (before ischemia), and after reperfusion, rCBF recovered to $>75\%$ of normal, which confirmed the success of the model of cerebral ischemia and reperfusion.

The concentrations of TAK-242 in plasma and brain tissue were detected by liquid chromatography with tandem mass spectroscopy. The results showing that the concentration of TAK-242 in plasma increased 3 hours after treatment, was maintained 8 hours after treatment, and decreased at 24 hours after treatment, was maintained 8 hours after treatment, and decreased at 24 hours after treatment, indicated that TAK-242 injected intraperitoneally can be absorbed into blood circulation and is maintained up to 24 hours after injection (Figure 1). Interestingly, the concentration of TAK-242 in brain tissue also increased after the injection, indicating that TAK-242 can pass through the BBB in the ischemic and nonischemic brain, and be maintained in brain tissue for at least 24 hours after injection (Figure 1). Previous studies have indicated that the pharmacokinetics of TAK-242 depends on the species and organs—it differs, for example, in dogs and rats, and the distribution of TAK-242 is different in plasma and kidney.\textsuperscript{21,24} However, the distribution of TAK-242 in mice plasma and brain after intraperitoneal injection has not been reported. In addition, in previous studies, the dosages of TAK-242 ranged from 1 to 10 mg/kg (including 3 mg/kg) in patients, guinea pigs, and mice via intravenous injection. Base on the previous reports, we modified the route of administration from intravenous injection to intraperitoneal injection. Our results confirmed that TAK-242 injected intraperitoneally could be absorbed into the blood stream, which was a new finding in the present study. Importantly, our data show for the first time that TAK-242 can cross the BBB and enter into ischemic and nonischemic hemispheres in mice after focal cerebral I/R induced by middle cerebral artery occlusion. Moreover, the concentration of TAK-242 in the ischemic hemisphere was significantly higher than that in the nonischemic hemisphere. This may be interpreted to indicate that cerebral I/R facilitates the capability of TAK-242 to cross the BBB, in the damaged brain.

To evaluate the neuroprotective effect of TAK-242 on ischemic brain, infarct size and neurologic function were measured 24 hours after cerebral I/R or sham surgery. As shown in Figure 2, our data showed that treatment with TAK-242 significantly reduced brain infarct size and significantly improved neurologic function compared with sham controls (\textit{P} < 0.05, Figures 2–6). Previous studies have shown that these cytokines are associated with ischemia-induced inflammatory responses, ischemic damage, and brain repair after cerebral I/R.\textsuperscript{25–34} For example, interleukin-6 is increased in the acute phase of stroke, and is considered a robust early marker for outcome in acute ischemic stroke.\textsuperscript{29} Monocyte chemotactic protein-1, MIP-1$\gamma$, and TIMP-1 play important roles in inflammatory processes and contribute to the pathogenesis of brain injury and neurologic dysfunction.\textsuperscript{31–36} Moreover, MMP family and COX are mediated by TLR4 signaling and involved in the progression of neuronal damage after cerebral ischemia.\textsuperscript{34,35} Our data showed that treatment with TAK-242 significantly reduced the levels of sTNF RII, monocyte chemotactic protein-1, MIP-1$\gamma$, TIMP-1, and the expression of MMP-9 and COX-2. The results show that administration of TAK-242 blocks TLR4-mediated signaling and inhibits \textit{in situ} inflammatory responses induced by cerebral I/R.

A limitation of the present study is that the tissues for assays on the concentrations of TAK-242 and the expression of inflammatory cytokines in brain tissue were harvested from entire cerebral hemisphere instead of specific brain tissues, such as cortex, striatum, and hippocampus. If the assays were performed in the individual...
CONCLUSION
In our data, we can be interpreted to show that TAK-242 can pass through the BBB and distribute in the nonischemic brain tissue and ischemic brain tissue in mice, and that administration of TAK-242 protects the brain from damage at the acute stage after cerebral I/R by inhibiting TLR4-mediated signaling and mediating the expression of inflammatory cytokines. These novel findings have the potential to lead to a new medication for ischemic stroke.

DISCLOSURE/CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
gestosterone. J Neuroinflammation 2011; 8: 42.

© 2015 ISCBFM